LeMaitre Vascular Inc (LMAT) reported quarterly earnings results on Wednesday, Jul-27-2016. The company said it had a profit of $0.14 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $0.11. The company posted revenue of $22.40 million in the period, compared to analysts expectations of $21.59 million. The company’s revenue was up 12.6% compared to the same quarter last year.
LeMaitre Vascular Inc opened for trading at $16.03 and hit $17.1 on the upside on Thursday, eventually ending the session at $16.59, with a gain of 13.40% or 1.96 points. The heightened volatility saw the trading volume jump to 3,34,791 shares. Company has a market cap of $305 M.
In a different news, on Jun 8, 2016, George W Lemaitre (Chairman and CEO) sold 19,189 shares at $15.03 per share price. According to the SEC, on Jun 8, 2016, Peter R Gebauer (President, International OP) sold 6,310 shares at $14.96 per share price. On Jun 7, 2016, Lawrence J Jasinski (director) sold 4,924 shares at $14.99 per share price, according to the Form-4 filing with the securities and exchange commission.
LeMaitre Vascular Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop manufacture and market medical devices and implants used primarily in the field of vascular surgery. The Company’s product lines include valvulotomes balloon catheters carotid shunts biologic patches biologic grafts radiopaque marking tape anastomotic clips remote endarterectomy devices laparoscopic cholecystectomy devices vascular grafts angioscopes and powered phlebectomy devices. The Company develops manufactures and markets vascular devices to address the needs of vascular surgeons. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart including the Expandable LeMaitre Valvulotome the Pruitt F3 Carotid Shunt VascuTape Radiopaque Tape and the XenoSure biologic patch.